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Abstract
Kaposi's sarcoma (KS) is a highly and abnormally vascularized tumor-like lesion affecting the skin,
lymphnodes and viscera, which develops from early inflammatory stages of patch/plaque to late,
nodular tumors composed predominant of spindle cells (SC). These SC are infected with the
Kaposi's sarcoma-associated herpesvirus or human herpesvirus-8 (KSHV/HHV-8). KS is promoted
during HIV infection by various angiogenic and pro-inflammatory factors including HIV-Tat. The
latency associated nuclear antigen type 1 (LANA-1) protein is well expressed in SC, highly
immunogenic and considered important in the generation and maintenance of HHV-8 associated
malignancies. Various studies favour an endothelial origin of the KS SC, expressing "mixed"
lymphatic and vascular endothelial cell markers, possibly representing hybrid phenotypes of
endothelial cells (EC). A significant number of SC during KS development are apparently not HHV8
infected, which heterogeneity in viral permissiveness may indicate that non-infected SC may
continuously be recruited in to the lesion from progenitor cells and locally triggered to develop
permissiveness to HHV8 infection. In the present study various aspects of KS pathogenesis are




Kaposi's sarcoma first described by Moritz Kaposi in 1872
as "idiopathic multiple pigmented sarcomas of the skin"
[1] is an angioproliferative, tumour-like lesion usually
developing in the skin [2], and eventually disseminating
to multiple cutaneous sites, viscera and lymph nodes. Pre-
viously a rare disease, it is now a global health care and
clinical problem because of its association with the HIV
pandemic [3] and other immunosuppressed states[4].
Four clinically different KS forms are now recognized [5]:
a) Classical or sporadic KS (CKS), originally described [1]
as a slow growing, indolent tumor mostly developing in
the extremities of elderly males of eastern and Mediterra-
nean Europe. b) Endemic KS (EKS), predominant in east-
ern and central sub-Saharan Africa before the AIDS
epidemic and clinically similar to CKS, but also seen in a
more fulminant and fatal form in children. The childhood
EKS is often lymphoglandular with or without skin
involvement. c) Acquired immunodeficiency syndrome
(AIDS)-associated KS (AKS), the most frequent tumor of
human immunodeficiency virus type I (HIV-l) infection
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and the most aggressive and rapidly growing form of KS in
AIDS, with early dissemination in the skin and viscera.
d) Iatrogenic KS (IKS), seen in drug related immunosup-
pressed patients, e.g. transplant patients, emphasizing the
importance of immune disturbance as a co-factor in the
pathogenesis of IKS and AKS, and possibly also EKS.
In spite of the clear clinical differences the histopathology
of the various KS forms is essentially the same, with char-
acteristic changes related to stage in the development of
the KS tumor[6].
The epidemiology of AKS led to the discovery of a novel
herpes virus [7], which subsequently was shown to be
associated with all clinico-epidemiological forms of KS
[8]. The virus was rapidly characterised as a KS associated
herpes virus (KSHV) and classified as human herpes virus
type 8 (HHV-8). It was soon recognized to also be associ-
ated with some rare types of lymphomas in AIDS patients,
namely primary effusion lymphoma or body-cavity-
based-lymphoma (PEL/BCBL) and Castleman's disease
(MCD)[9].
Human herpesvirus type 8 (HHV-8)
Human herpesvirus 8 or Kaposi's sarcoma associated her-
pesvirus (HHV-8/KSHV) was recognized to be a novel
gamma-2 herpesvirus of the rhadinovirus genus closely
related to the human gamma -1 herpesvirus, Epstein-Barr
virus (EBV) [10].
A number of viral glycoproteins have been characterized
shown to bind to cell surface heparan sulfate [11] and the
cell receptor integrin α3β1, respectively, thereby mediat-
ing virus entry through endocytosis [12]. In the KS lesion
HHV-8 is predominantly found in the so called tumor
spindle (SC) cells in KS but was also in some lym-
phocytes, monocytes and keratinocytes [13]. The virus
replicates in either a lytic or predominantly in the latent
form as closed circular episomal DNA [14] within the
nucleus of KS tumor cells (SC) and B cells of MCD and
other infected mononuclear cells [15]. It has been shown
that the episomal viral DNA is tethered to metaphase
chromosomes and copied in tandem with host cell DNA
during cell division [16]. Latent viral specific genes well
demonstrated in infected KS SC are the latent nuclear anti-
gen (LANA-1), viral cyclin (v-cyclin), v-FLIP and kaposin
a small membrane protein, which are all adjacent in the
genome [16]. Lytic virus expression is most frequent in
MCD, moderate in KS and relatively rare in PEL cells.
Common viral genes found during lytic expression
include K1 transmembrane protein, v-GCR, v-IRF, v-IL-6
and v-MIP [15].
LANA-1
The latency associated nuclear antigen type 1 (LANA-1)
protein is a well expressed and highly immunogenic,
latent nuclear antigen of HHV-8 considered important in
the generation and maintenance of HHV-8 associated
malignancies [17] by its cell cycle regulation in competing
with E2F for binding of hypophosphorylated pRb thus
freeing E2F to activate gene transcription involved in cell
cycle progression [18] (Fig 1). E2F activity can also trigger
apoptosis via the p53 pathway but LANA-1 interacts with
p53, repressing its gene transcriptional activity and ability
to induce apoptosis (Fig 1). Therefore the inhibition of
p53 by LANA-1 allows latent HHV-8 to promote cell cycle
progression whilst inhibiting apoptosis [19]. Oncogenic
viruses often block cell differentiation during tumor
development by the stabilization of beta-catenin which
also appears to be promoted by LANA [20].
The LANA-1 antigen is well detectable by immunohisto-
chemistry also in routinely formalin fixed paraffin embed-
ded biopsies. It is expressed by most SC in both early and
late stage lesions of all different clinical KS forms (AKS,
EKS, CKS and IKS) [8,21] and therefore used as a diagnos-
tic marker in suspected HHV-8 related lesions and also for
serology of LANA-1 antibodies in patients by immunocy-
tochemistry that gives a characteristic speckled nuclear
staining on HHV-8 infected BCBL cells. Several studies
have shown an increase in LANA-1 positive cells during
progression of KS lesions [22,23] allowing quantification
and phenotyping of these cells in KS lesions.
Pathogenesis of KS
HHV-8 is the most recently identified human oncogenic
herpesvirus [24] expressing candidate viral oncogenes
which constitutively activate growth-signalling pathways
[13,25]. The pathogenesis of KS is however still unclear
and appears complex, involving various mechanisms
dependent on both viral and cellular activities related to
inflammation and angiogenesis promoted by endothelial
growth factors (β-FGF, PDGF, VEGF) including HIV-Tat as
well as cell proliferation and anti-apoptosis (vBCL2)
[2,13,26,27]. Characteristic for HHV-8 is the high hom-
ology of several viral and cellular genes suggesting viral
genes were pirated from host chromosomes during viral
evolution. Some of these genes are involved in down
modulating the host immune responsiveness to target,
infected cells and modulate cell proliferation, cell differ-
entiation and angiogenesis [13], including genes as vBcl-
2, vIL-8R, vMIPs, vIL-6, and the D type viral cyclin
The HHV-8 infected cells escape immune response target-
ing by down regulation of surface MHC mediated by two
transmembrane proteins, MIR1 and MIR2 [28] (Fig 1),
which promote MHC endocytosis, and lysosomal degra-
dation (Fig 1). Downregulation of MHC I and its acces-Infectious Agents and Cancer 2007, 2:4 http://www.infectagentscancer.com/content/2/1/4
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sory immune receptors poses the risk of initiating a
natural killer (NK) cell response by initiating apoptosis
through Fas (CD95/Apo-1) in cells lacking appropriate
MHC I expression. However, HHV-8 can inhibit NK-
mediated killing through expression of the anti apoptotic
v-FLICE-inhibitory proteins (v-FLIPs) [28]. V-FLIP which
acts as a dominant inhibitor of receptor-activated apopto-
sis by binding to Fas-associated death domain protein and
caspase 8 (FLICE) [29]. This prevents activated caspase
recruitment into the death-inducing signaling complex
(Fig 1).
HHV-8 v-FLIP shares with c-FLIPs the ability to activate
NF-κB [28] which is essential for the growth and survival
of the cell. Our studies on KS biopsies have shown that
apoptosis clearly decreases during development of early to
late nodular KS lesions [30], and that the expression of
anti-apoptotic v-FLIP and cellular Bcl-2 increase from
early to late stage KS lesions, [30,31]. Thus viral exploita-
tion of these two anti-apoptotic pathways contributes to
the tumor-like growth and progression of the KS lesion.
V-cyclin binds with cyclin dependent kinases (CDK6),
which complex phosphorylates pRb, releasing a transcrip-
tion factor (E2F), which activates the transcription of S-
phase genes (Fig 1). However, unlike cellular cyclin, vCy-
clin-CDK6 complexes are resistant to CDK inhibitory pro-
teins, which may lead to unregulated cell cycle
progression and transformation and thereby promote
tumor development [32].
Kaposin, the latency gene represents a potential viral
oncogene and is characterized as a transforming gene
[33], although little is known about its role in deregulat-
ing cell signalling [34]. It is present in three (A, B, C) iso-
forms [35] of which Kaposin B is expressed by all HHV-8
HHV-8 gene expression (pathogenesis) during SC development and tumor growth Figure 1
HHV-8 gene expression (pathogenesis) during SC development and tumor growth.Infectious Agents and Cancer 2007, 2:4 http://www.infectagentscancer.com/content/2/1/4
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infected cells and can activate the p38-MK2 pathway [36]
(Fig 1) and block the degradation of the messenger RNAs
transcribing various cytokines necessary for cell survival,
hence increasing their translation [36]. The Kaposin gene
also encodes several microRNAs (miRNA), which may
regulate gene expression by binding to complementary
messenger RNAs [37]. Two of these HHV-8 miRNAs are
expressed by SC at all KS stages [37] and may contribute
to tumorigenic transformation of infected cells [33], and
therefore of therapeutic interest [37].
The KSHV miRNAs are expressed from what appears to be
a single genetic locus that largely coincides with an 4-kb
noncoding sequence located between the KSHV v-cyclin
and K12 Kaposin genes, both of which are also expressed
in latently infected cells. Computer analysis of potential
mRNA targets for these viral miRNAs identified a number
of interesting candidate genes, including several mRNAs
previously shown to be downregulated in KSHV-infected
cells. It appears that these viral miRNAs play a critical role
in the establishment and or maintenance of KSHV latent
infection and hence, in KSHV-induced oncogenesis [38].
HHV-8 also encodes a G-protein-coupled receptor
(vGCR) homolog to the human angiogenic, chemokine
interleukin-8 receptor (IL-8R, CCR1 and CXCR2) [39] (Fig
1). Angiogenic responses induced by vGCR are mediated
by upregulation of vascular endothelial growth factor
(VEGF) [40]. The constitutive activity of vGCR could
therefore have a role for VEGF expression by SC during the
development of early stage KS lesions [41]. Furthermore
the vGCR dependent expression of autocrine and para-
crine growth factors (bFGF, VEGF,) promotes the angio-
genesis and edema [26,42] seen in KS patients. It was also
shown [43] that viral envelop glycoprotein gB can activate
the VEGFR-3 receptor and trigger receptor signalling on
the surface of microvascular endothelial cells, thereby
modulating cell migration and proliferation. VEGFR-3
expression and activation may also enhance HHV-8 infec-
tion and participate in HHV-8 mediated transformation
[43] and thereby appears to be an important factor in the
pathogenesis of Kaposi's sarcoma.
The Kaposi sarcoma herpesvirus (KSHV) also encodes
multiple proteins that disrupt host antiviral responses,
including four viral proteins that have homology to the
interferon regulatory factor (IRF) family of transcription
factors. At least three of the KSHV vIRFs (vIRFs 1–3) alter
responses to cellular IRFs and to interferons (IFNs). The
vIRFs also affect other important regulatory proteins in
the cell, including responses to transforming growth fac-
tor beta (TGF-beta) and the tumor suppressor protein p53
[44]. K7/vIAP (inhibitor of apoptosis protein) is another
antiapoptotic factor homologous to the cellular protein
survivin [45].
Histogenesis of KS
The histopathology of KS is characterized by an early infil-
tration of mononuclear inflammatory cells, formation of
small, irregular, endothelial lined slits around new blood
vessels (angiogenesis) and extravasation of erythrocytes
[2] with accumulation of hemosiderin pigments. KS at
early stages appears to reflect a predominantly reactive cell
proliferation of polyclonal nature that may regress, but
usually progresses to a nodular possibly clonal tumor
[2,46]. Pathognomonic for KS development from early
patch/plaque to late nodular tumor lesions is the
increased appearance of bundles of morphological spin-
dle cells (SC) expressing CD34 (hematopoietic stem cell
and vascular endothelial marker). At the late nodular KS
stage there is less inflammatory cell infiltration, mostly
around the boaders of the dense, nodular accumulation of
SC bundles which skin lesions may later ulcerate. Unlike
typical metastatic cancers, KS often appears early as a mul-
ticentric tumour, with each lesion arising de novo by a
localized small patch and of SC [47].
Most SC are positive for CD34 and LANA but a consider-
able number of CD34+ SC are LANA- at all AKS/EKS
stages [22,23]. This apparent heterogeneity in viral per-
missiveness of CD34+ SC seems less compatible with a
clonal CD34+ SC proliferation and virus transfer but
appears to indicate that also non-infected CD34+ SC are
continuously recruited from progenitor cells and locally
triggered to develop permissiveness to HHV-8 infection
[22,23]. Furthermore cells belonging to the non-cycling
SC (Ki67-) population showed a clear increase during
development from patch/plaque (median 13.5%) to nod-
ular stage (median 40.3%) [22], also supporting the con-
cept of continuous recruitment of CD34+ cells to the
lesion. KS spindle-like cells have been shown to develop
in cultures of peripheral blood of HIV infected patients
with KS or at high risk for developing KS [48]. Further-
more recent studies show that endothelial cells or their
precursors residing in donor kidneys may contribute to
post-renal transplant KS indicated by the finding that KS
SC in the female recipient kidney had a male (donor)
karyotype and that KS SC expressed the donor HLA anti-
gen [49]. These findings appear to indicate that KS SC
and/or their progenitors can be recruited during develop-
ment of KS lesion.
Characteristic spindle cells (SC) express various "mixed"
(LEC and VEC) endothelial phenotypic cell markers pos-
sibly representing hybrid phenotypes of endothelial cells
at different maturation stages. It has been recurrently
debated whether SC are vascular (VEC) or lymphatic
(LEC) in origin or derive from mesenchymal progenitor
cells [50-52], although most studies by immunohisto-
chemistry have revealed that SC express lymphatic mark-
ers, such as D2-40 [53], LYVE-1 [50] and VEGFR-3 [51].Infectious Agents and Cancer 2007, 2:4 http://www.infectagentscancer.com/content/2/1/4
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Also studies by gene expression microarray show that KS
neoplastic cells are closely related to lymphatic endothe-
lial cells (LEC) but coexpressing some blood vascular
endothelial cell (VEC) markers [54]. Furthermore HHV-8
can infect both LEC and VEC in vitro and infected LEC
had a higher HHV-8 genome copy number than VEC[54].
In-vitro infection of CD34+ human dermal microvascular
endothelial cells (HDMEC) with HHV-8 resulted in the
upregulation of LEC markers such as LYVE-1 in the
infected HDMEC [55].
In our study all LANA+ cells were LYVE-1+ (lymphatic
endothelial markers) in early and late KS and the HHV-8
infection (LANA) appeared better correlated to LYVE-1
than to CD34 expression [23]. LANA+/CD34-cells were
more frequent in early as compared to late lesions and did
not express a leucocytic phenotype (CD3, CD20, CD45,
CD68) [22], but most expressed lymphatic endothelial
(LEC) markers such as LYVE-1, VEGFR-3 and D2-40, sug-
gesting that resident LECs represent an early target of pri-
mary HHV-8 infection [23]. This is also supported by
other findings [54] that infected LECs have a higher HHV-
8 genome copy number than VECs. Obviously a high viral
copy number may result in an efficient maintenance and
propagation of episomal HHV-8 DNA in dividing and
migrating LECs. Furthermore in-vitro activation of
VEGFR-3 by HHV-8 has been shown to increase endothe-
lial cell migration and to enhance cell susceptibility to
HHV-8 infection and transformation [43]. Hence, the
activation of VEGFR-3 in LANA+/VEGFR-3+ SC observed
during KS development will probably promote an
increased endothelial cell migration (recruitment) and
transformation to tumor SC including formation of path-
ological vascular slits.
Cell proliferation is relatively low in KS as shown by our
previous studies on proliferation related protein Ki67
expression and DNA flow cytometry [30]. The frequency
of proliferating (Ki67+) cells usually decreased during
development from early to late KS lesions, consistent with
the notion that KS growth from a early reactive lesion to a
nodular tumor depends not only on SC division but also
on decreased apoptosis [30] and progenitor recruitment
[22,23]. No significant difference in cell proliferation was
observed between nodular AKS and EKS [22]. These find-
ings could therefore indicate that the usually more spread
and aggressive growth of the AKS tumors may reflect a
higher rate of SC progenitor recruitment compared to the
more indolent EKS lesions.
Cytogenesis of KS
Reports on cytogenetic and molecular genetic changes in
KS are few [56]. Studies from KS cell lines, KS Y-1 (AKS
derived) and KS SLK (IKS derived) revealed loss of copies
of chromosomes 14 and 21 and non-random transloca-
tions and deletions in the short arm of chromosome 3 at
region 3p14. These KS cell lines also exhibit loss of heter-
ozygosity of loci at region 3p14-ter. The chromosome 3
alterations observed were suggested to contribute to the
neoplastic process in KS [57] but other cytogenetic studies
on the KS-IMM cell line (IKS) [56] showed gains in
1q10→qter, 7p10→pter, 7q22→qter, 8p11→qter,
14pter→q22 but no changes in chromosome 3 [56].
These aberrations are compatible with the notion that ini-
tially KS may develop as a reactive polyclonal cell prolifer-
ation associated with chromosome instability, followed
by acquisition of clonal chromosome changes in later
stages [56]. However, the significance in KS pathogenesis
of aberrations on established KS cell lines should be
related to finding that such cell lines when established
usually loose their HHV-8 episomes and possibly may
represent only a minor KS cell population.
The chromosomal instability suggested by the studies on
cell lines may lead to cell apoptotis via the p53 path-
way[58]. However, HHV-8 LANA binds to p53repressing
its ability to induce apoptosis [59]. Furthermore telomer-
ase activity has been found to be upregulated in KS [60],
which may immortalise the infected cell leading to
increased tumor cell survival.
Previous, CGH studies of formalin fixed paraffin embed-
ded KS biopsies revealed a recurrent gain at 11q13 [61],
which also amplifies two known oncogenes, FGF4 and
INT2, residing at 11q13 suggesting a possible role of
HHV-8 in the amplification and activation of genomic
oncogenes [61].
Loss of chromosome Y was observed in most AKS and EKS
cases recently studied by us [62] and interestingly it was
the only aberration observed in early KS. Late stage (nod-
ular) KS had beside loss of chromosome Y, also recurrent
deletions on chromosomes 16 and 17. Deletion of chro-
mosome Y was also reported by previous studies on short
term cultures of primary KS tumor cells and established
KS cell lines [56]. EKS showed often more chromosomal
abnormalities than AKS [62], which might indicate that
genomic instability could be a more important factor in
the development of EKS than AKS. Most likely AKS devel-
opment is also promoted by various cytokines and growth
factors produced by the HIV infection and the dysregu-
lated and compromised state of host immune response.
Loss of the Y chromosome and encoded male specific
minor histocompatibility antigens (HY antigen) has been
shown to be linked to haematological relapse in acute
lymphoblastic leukemia due to immune escape mecha-
nisms [63]. The HY antigens are presented at the cell sur-
face with the major histocompatibility complex (MHC)
and together also processed intracellularly [64]. However,
no studies have previously indicated a deficiency of HYInfectious Agents and Cancer 2007, 2:4 http://www.infectagentscancer.com/content/2/1/4
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antigen in KS tumors, which loss of the Y chromosome in
our studies suggests as of possible importance in KS
pathogenesis.
HIV pathogenesis in KS
There seems to be a cross talk between HIV-1 and HHV-8
as recent studies have shown that HIV-1 replication stim-
ulates HHV-8 production in PEL cell lines and peripheral
blood mononuclear cells from KS patients, possibly due
to the activating functions of HIV-Tat [65, 66] ORF50, the
major transactivator of HHV-8 lytic cycle can also induce
increased levels of HIV replication by interacting synergis-
tically with HIV-1 Tat leading to increased cell susceptibil-
ity to HIV infection and transient permissiveness to HIV
replication [67].
The increased incidence of KS in patients with AIDS was
also shown to be related to effects of the HIV-1 Tat protein
by stimulation of proliferation and anti-apoptosis of
infected spindle cells (SC) and also activation of HHV-8
thus increasing SC viral load and expression of various
viral genes with oncogenic potential (vGCR, vBCL2, and
vIRF1, see above) [65]. Thus, Tat promotes tumorigenesis
of endothelial cells, both via stimulation of vascular
endothelial growth factors, anti-apoptotic activity and
HHV-8 replication. Notably, the functional activity of Tat
protein in the pathogenesis of AKS clearly involves an
intercellular signalling cascade which is inhibited by anti-
bodies to HIV-Tat epitopes [68, 69].
Recently we have found differences in SC viral load
between oral and cutaneous KS lesion also suggesting pos-
sible differences of Tat expression in these lesions [70].
In summary the concept of oncogenesis related to infec-
tion is particularly well exemplified by the herpes virus
HHV-8 and retrovirus HIV-1 associated Kaposi's sarcoma,
which develops due to the effects of various host-cells and
viral factors elicited during infection affecting cell prolifer-
ation, cell escape from apoptosis and dysregulation of
host immune responses.
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